A non-compulsory stewardship programme for the management of antifungals in a university-affiliated hospital

Clinical Microbiology and Infection

Volumn 19, Issue 1, 2013, Pages 56-61

  Lopez Medrano F ^a   San Juan, R ^a   Lizasoain, M ^a   Catalan M ^a   Ferrari, J M ^a   Chaves, F ^a   Lumbreras, C ^a   Montejo, J C ^a   Herreros de Tejada, A ^a   Aguado, J M ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Antifungals; Candida; Cost; Resistance; Stewardship

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; ASPERGILLUS; CANDIDA; CANDIDEMIA; COST CONTROL; DRUG CONTROL; DRUG COST; HEALTH CARE QUALITY; HEALTH PROGRAM; HUMAN; MORTALITY; MYCOSIS; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT WITHDRAWAL; UNIVERSITY HOSPITAL;

CANDIDA; FUNGI;

EID: 84871619928     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2012.03891.x     Document Type: Article

References (17)

1. Lesprit P, Brun-Buisson C. Hospital antibiotic stewardship. Curr Opin Infect Dis 2008; 21: 344-349.
2. Doron S, Davidson LE. Antimicrobial stewardship. Mayo Clin Proc 2011; 86: 1113-1123.
3. Munoz P, Guinea J, Rojas L, Bouza E. New antifungal agents for the treatment of candidaemia. Int J Antimicrob Agents 2010; 36 (suppl 2): S63-S69.
4. Apisarnthanarak A, Yatrasert A, Mundy LM. Impact of education and an antifungal stewardship program for candidiasis at a Thai tertiary care center. Infect Control Hosp Epidemiol 2010; 31: 722-727.
5. Lopez-Medrano F, San Juan R, Serrano O et al. Impact of a non-compulsory antibiotic control program (PACTA): cost reductions and decreases in some nosocomial infections. Enferm Infecc Microbiol Clin 2005; 23: 186-190.
6. Hughes WT, Armstrong D, Bodey GP et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-751.
7. Solomkin JS, Mazuski JE, Baron EJ et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003; 37: 997-1005.
8. Stevens DA, Kan VL, Judson MA et al. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis 2000; 30: 696-709.
9. Pappas PG, Rex JH, Sobel JD et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38: 161-189.
10. WHO Collaborating Centre for Drug Statistics Methodology. Available at: http://www.whocc.no/atc_ddd_index/ (last accessed 18 January 2012).
11. World Health Organization. International Classification of Diseases, Version 2007. Available at: http://www.who.int/classifications/icd/en/ (last accessed 18 January 2012).
12. De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-1821.
13. Drew RH. Antimicrobial stewardship programs: how to start and steer a successful program. J Manag Care Pharm 2009; 15 (2 suppl): S18-S23.
14. Dellit TH, Owens RC, McGowan JE Jr et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44: 159-177.
15. Scott LJ, Simpson D. Voriconazole: a review of its use in the management of invasive fungal infections. Drugs 2007; 67: 269-298.
16. Gutierrez F, Wall PG, Cohen J. An audit of the use of antifungal agents. J Antimicrob Chemother 1996; 37: 175-185.
17. Sutepvarnon A, Apisarnthanarak A, Camins B, Mondy K, Fraser VJ. Inappropriate use of antifungal medications in a tertiary care center in Thailand: a prospective study. Infect Control Hosp Epidemiol 2008; 29: 370-373.